FDA grants exa-cel priority review, with decision due by year's end | Sickle cell disease CRISPR
The FDA granted priority review to the CRISPR gene-editing therapy exa-cel for sickle cell disease, with an approval decision due by Dec. 8.
The FDA granted priority review to the CRISPR gene-editing therapy exa-cel for sickle cell disease, with an approval decision due by Dec. 8.